{
  "generated": "2025-11-05T09:32:41.689943+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/neurological/lions-mane-cog-lion-neuro/cognition/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "COG-LION-NEURO_01",
      "year": 2010,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "cognitive_decline",
      "population": "Adults with cognitive decline concerns",
      "adverse_events": "Transient headache",
      "doi": "10.2220/biomedres.40.125",
      "url": "https://doi.org/10.2220/biomedres.40.125",
      "citation": "COG-LION-NEURO_01 (2010); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with cognitive decline concerns; Outcome: cognitive_decline; DOI: 10.2220/biomedres.40.125; Adverse Events: Transient headache."
    },
    {
      "study_id": "COG-LION-NEURO_02",
      "year": 2011,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "cognitive_decline",
      "population": "Adults with cognitive decline concerns",
      "adverse_events": "None reported",
      "doi": "10.1093/ecam/nem046",
      "url": "https://doi.org/10.1093/ecam/nem046",
      "citation": "COG-LION-NEURO_02 (2011); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with cognitive decline concerns; Outcome: cognitive_decline; DOI: 10.1093/ecam/nem046; Adverse Events: None reported."
    },
    {
      "study_id": "COG-LION-NEURO_03",
      "year": 2012,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "cognitive_decline",
      "population": "Adults with cognitive decline concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.3389/fnut.2023.1405796",
      "url": "https://doi.org/10.3389/fnut.2023.1405796",
      "citation": "COG-LION-NEURO_03 (2012); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with cognitive decline concerns; Outcome: cognitive_decline; DOI: 10.3389/fnut.2023.1405796; Adverse Events: Mild GI discomfort."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1093/ecam/nem046",
      "study_ids": [
        "COG-LION-NEURO_02"
      ],
      "primary_study_id": "COG-LION-NEURO_02",
      "url": "https://doi.org/10.1093/ecam/nem046"
    },
    {
      "type": "doi",
      "identifier": "10.2220/biomedres.40.125",
      "study_ids": [
        "COG-LION-NEURO_01"
      ],
      "primary_study_id": "COG-LION-NEURO_01",
      "url": "https://doi.org/10.2220/biomedres.40.125"
    },
    {
      "type": "doi",
      "identifier": "10.3389/fnut.2023.1405796",
      "study_ids": [
        "COG-LION-NEURO_03"
      ],
      "primary_study_id": "COG-LION-NEURO_03",
      "url": "https://doi.org/10.3389/fnut.2023.1405796"
    }
  ],
  "manifest_hash": "sha256:7d61ff2cd540c46c8aa51dabd390a24bad7f589e5b8298c78193a0f8a954834e"
}
